Results from 2 major clinical studies, Checkmate 057[47] and Keynote-010,[48] both suggest that patients with high PD-L1 expression in tumor tissues benefit more from anti-PD-1/PD-L1 immunotherapy. Here, CD274 is linked to neoplasm.